两种基于外膜蛋白的B群脑膜炎球菌有效疫苗在冰岛年轻人中的免疫原性。
Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland.
作者信息
Perkins B A, Jonsdottir K, Briem H, Griffiths E, Plikaytis B D, Hoiby E A, Rosenqvist E, Holst J, Nokleby H, Sotolongo F, Sierra G, Campa H C, Carlone G M, Williams D, Dykes J, Kapczynski D, Tikhomirov E, Wenger J D, Broome C V
机构信息
Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
出版信息
J Infect Dis. 1998 Mar;177(3):683-91. doi: 10.1086/514232.
Serum bactericidal activity (SBA) and ELISA antibody levels elicited by two efficacious serogroup B meningococcal vaccines were measured in a controlled trial involving 408 15- to 20-year-olds. Subjects were given two doses at a 6-week interval of a serogroup B or control vaccine. Response was defined as > or = 4-fold rise in antibody level. After two doses of the Finlay Institute (Havana) vaccine at 12 months, the proportions of SBA and ELISA responders were not different from those of the control group (15% and 17% [vaccine] vs. 13% and 9% [control], P > .05). After two doses of the National Institute of Public Health (Oslo) vaccine, there were more SBA and ELISA responders than in the control group (47% and 34% [vaccine] vs. 10% and 1% [control]) or the Finlay Institute vaccine group (P < .05 for both). SBA and ELISA may be insensitive correlates for protective efficacy for some outer membrane protein-based serogroup B meningococcal vaccines.
在一项涉及408名15至20岁人群的对照试验中，测量了两种有效的B群脑膜炎球菌疫苗引发的血清杀菌活性（SBA）和ELISA抗体水平。受试者每隔6周接种两剂B群疫苗或对照疫苗。反应定义为抗体水平升高≥4倍。在接种两剂哈瓦那芬莱研究所疫苗12个月后，SBA和ELISA反应者的比例与对照组无差异（疫苗组分别为15%和17%，对照组分别为13%和9%，P>.05）。接种两剂奥斯陆国家公共卫生研究所疫苗后，SBA和ELISA反应者比对照组（疫苗组分别为47%和34%，对照组分别为10%和1%）或芬莱研究所疫苗组更多（两者P<.05）。对于某些基于外膜蛋白的B群脑膜炎球菌疫苗，SBA和ELISA可能不是保护性效力的敏感相关指标。
Zotero 插件